November 21, 2018 PR-M11-18-NI-072
DUBLIN /PRNewswire/ -- The "Blockbuster Oncology Brands Market Size, Share & Trends Analysis Report By Brand (Opdivo, Revlimid, Zejula), By Indication (Lung Cancer, Lymphoma, Multiple Myeloma), And Segment Forecasts, 2018 - 2027" report has been added to ResearchAndMarkets.com's offering.
The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, progressing at a CAGR of 7.3% during the forecast period.
Shift towards immunotherapies coupled with increasing number of indication expansion trials is one of the primary growth stimulants for the market.
Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo's sales, while Revlimid's patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immuno-therapeutic is expected to trail behind the latter by 2027.
Lifecycle management strategies, including expansion of approved indications and development of combination therapies, underline competitive dynamics in the global blockbuster oncology brands market. Collaborative agreements signed by participating companies facilitate development, commercialization, and regional expansion of products. Such strategies not only enable players to gain easy access into new markets, but also allow them to leverage scientific and technological expertise of their collaborative partner.
Further key findings from the report suggest:
Key Topics Covered:
Chapter 1 Methodology And Scope
1.1 Research Methodology
1.2 Research Scope And Assumptions
1.3 List Of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
Chapter 4 Market Definitions
Chapter 5 Industry Outlook
5.1 Business Segment Trend Analysis
5.2 Pricing Analysis
5.3 Market Variable Analysis
5.3.1 Market Drivers Analysis
5.3.1.1 Accelerated Approvals Expedite Market Launch
5.3.1.2 Immuno-Oncology Therapies As First Line Treatment
5.3.2 Market Restraints Analysis
5.3.2.1 High Therapy Costs Hinders Market Access
5.4 Business Environment Analysis Tools
5.4.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological)
5.4.2 Porter's Five Forces Analysis
Chapter 6 Competitive & Vendor Lanscape
6.1 Market Participation Categorization
6.1.1 Market Leaders
6.1.2 Innovators
6.2 Strategic Initiatives & Outcome Analysis
6.2.1 List Of Key Strategies, By Company
6.4 List Of Key Companies, By Region
6.5 List Of Key Companies, By Indication
6.6 List Of Key Companies, By Brands
6.7 Company Market Share Analysis
Chapter 7 Regulatory And Political Forces
7.1 Regulatory Landscape
7.1.1 North America
7.1.2 Europe
7.1.3 Asia Pacific
7.1.4 Middle East & Africa
7.1.5 Latin America
Chapter 8 Brands Business Analysis
8.1 Blockbuster Oncology Brands Market: Brand Analysis
8.1.1. Tagrisso
8.1.2 Tecentriq
8.1.3 Ibrance
8.1.4 Perjeta
8.1.5 Zejula
8.1.6 Gazyva
8.1.7 Revlimid
8.1.8 Darzalex
8.1.9 Imbruvica
8.1.10 Opdivo
8.1.11 Keytruda
Chapter 9 Indications Business Analysis
9.1. Blockbuster Oncolgoy Brands: Indications Movement Analysis
9.1.1. Lung Cancer
9.1.2 Breast Cancer
9.1.3 Multiple Myeloma
9.1.4 Lymphoma
9.1.5 Others
Chapter 10 Regional Business Analysis 2015-2027
Chapter 11 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/mhthck/global_60?w=5
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Our purpose is simple - to enable intelligent decision making.
15 years ago we began selling market research reports. Today we are the world's largest market research store - connecting global information professionals with market insights and analysis from 1,700 research teams based across 81 countries.
We are proud to count over 450 of the Fortune 500 as our clients.